Dubbed CoLab, the Battelle Drug Discovery CoLaborative aims to bring together a variety of industry-leading companies to deliver the highest quality of mid- to late-stage drug discovery services through a single, integrated approach. The overall goal is to de-risk drug candidates earlier in the discovery phase, which could potentially save significant time and money for pharmaceutical and biotechnology companies.
The CoLab is a unique approach that brings together external collaborators who are experts in their specific fields with Battelle’s internal expertise to provide the best research available for the mid- to late-stage discovery phase of pharmaceutical research. The combination of these services within the CoLab provides consistency, accountability and the ability to condense the development timeline.
Battelle is making the announcement at the Cambridge Healthtech Institute’s 11th Annual World Pharma Congress being held in Philadelphia, June 5-7.
“This advanced approach to drug discovery – and the foresight our leaders have shown in the development of the CoLab – displays Battelle’s leadership and commitment to improving global health through innovative ideas,” said Barbara Kunz, president of Battelle’s Health and Life Sciences. “Battelle is one of the few organizations that can bring industry experts together to work toward a common cause of improving the efficiency and cost of pharmaceutical development.”
In addition to Battelle, the CoLab will include The Ohio State University’s Wright Center of Innovation in Biomedical Imaging, Zenas Technologies, and Molecular Imaging, Inc.